Despite several steps forward in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), however there are still pending issues and upcoming challenges requiring adequate addressing in order to optimize the clinical management of metastatic patients harboring molecular alterations within the EGFR gene. This review aims to summarize the most recent findings regarding the diagnostic testing and therapeutic strategies of EGFR-mutant advanced NSCLC.

Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review

Passiglia, Francesco;Bironzo, Paolo;Bertaglia, Valentina;Listì, Angela;Garbo, Edoardo;Scagliotti, Giorgio Vittorio
2022-01-01

Abstract

Despite several steps forward in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), however there are still pending issues and upcoming challenges requiring adequate addressing in order to optimize the clinical management of metastatic patients harboring molecular alterations within the EGFR gene. This review aims to summarize the most recent findings regarding the diagnostic testing and therapeutic strategies of EGFR-mutant advanced NSCLC.
2022
11
5
935
949
Epidermal growth factor receptor (EGFR); combinations; next-generation sequencing (NGS); non-small cell lung cancer (NSCLC); resistance; targeted therapy
Passiglia, Francesco; Bironzo, Paolo; Bertaglia, Valentina; Listì, Angela; Garbo, Edoardo; Scagliotti, Giorgio Vittorio
File in questo prodotto:
File Dimensione Formato  
64084-PB5-6216-R4.pdf

Accesso aperto

Dimensione 403.34 kB
Formato Adobe PDF
403.34 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1870469
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact